5hcd: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 8: / Line 8: @@
 <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5hcd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hcd OCA], [https://pdbe.org/5hcd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5hcd RCSB], [https://www.ebi.ac.uk/pdbsum/5hcd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5hcd ProSAT]</span></td></tr>
 </table>
-== Disease ==
-[https://www.uniprot.org/uniprot/CO5_HUMAN CO5_HUMAN] Defects in C5 are the cause of complement component 5 deficiency (C5D) [MIM:[https://omim.org/entry/609536 609536]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis.  Note=An association study of C5 haplotypes and genotypes in individuals with chronic hepatitis C virus infection shows that individuals homozygous for the C5_1 haplotype have a significantly higher stage of liver fibrosis than individuals carrying at least 1 other allele (PubMed:15995705).
 == Function ==
-[https://www.uniprot.org/uniprot/CO5_HUMAN CO5_HUMAN] Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.  Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. C5a also stimulates the locomotion of polymorphonuclear leukocytes (chemokinesis) and direct their migration toward sites of inflammation (chemotaxis).
+[https://www.uniprot.org/uniprot/C5I2_RHIMP C5I2_RHIMP] Complement inhibitor (PubMed:27018802). Prevents complement-mediated C5 activation by binding to C5 (PubMed:27018802). Binds C5 at a different binding site than the other tick complement inhibitors OmCI and CirpT1, and the drug eculizumab (By similarity).[UniProtKB:A0A146B485]<ref>PMID:27018802</ref>
 <div style="background-color:#fffaf0;">
 == Publication Abstract from PubMed ==